Adherence to medication can be thought of as a decision making process that includes the consideration of the pros and cons of change. It involves evaluation on self-efficacy to change and attitudes held about the efficacy of medication treatment. HIV infected people who are sick, who are experiencing HIV symptoms or the negative side effects of their medications. A quality patient-provider relationship can also be identified as an important source of adhering to HIV medications. Understanding the predicament of the majority of HIV positive persons, conceived a breakthrough in HIV treatment administration. Surely, there are ways anyone can do to better adhere to ones treatment regimens but Vonavir/Atripla took all the burden away.
Atripala is the first multi-class
antiretroviral drug available in the United States and marked the first collaboration of two US pharmaceutical companies to combine their patented anti-HIV drugs into one product. It was approved by the Food and Drugs Administration on July 12, 2006. Atripla is the result of unprecedented effort between Gilead Sciences the manufacturer of Emtriva and Viread, with Bristol-Myers Squibb the maker of Sustiva.This wonderful innovation of a pill combines the active ingredients of Sustiva (efavirenz) a Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) with Emtriva (emtricitabine) and Veriad (tenofovir disoproxil fumarate), two Nucleoside Reverse transcriptase Inhibitor (NRTI). Dosing of Atripla is suitable to be taken at bedtime to improve tolerability of the nervous system and it is not recommended for HIV patients under 18 years old.
Mild to moderate rash is a common side effect of efavirenz. In controlled clinical trials, 26% of patients treated with efavirenz experienced new-onset skin rash compared with 17% of patients treated in control groups. Skin discoloration, associated with emtricitabine, may also occur. ATRIPLA should be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement, or fever. Atripla can significantly simplify a drug treatment regimen by reducing the pill burden, helping to increase adherence and thus reducing potential development of viral resistance to the drugs. This may result in longer term effectiveness of the drug regimen. Learn more, symptoms of HIV